Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04406272 · ClinicalTrials.gov registry record · Phase 2
VB-111 in Surgically Accessible Recurrent/Progressive GBM
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04406272 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT04406272, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
Interventions
- DRUG Bevacizumab
- OTHER Placebo
- PROCEDURE Surgery
- DRUG VB11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04406272
The ClinicalTrials.gov registry entry for NCT04406272 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT04406272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04406272 about?
NCT04406272 is a clinical study titled "VB-111 in Surgically Accessible Recurrent/Progressive GBM". This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
What is the current status of trial NCT04406272?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-08-01. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT04406272?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (OTHER), Surgery (PROCEDURE), VB11 (DRUG).
Who is sponsoring clinical trial NCT04406272?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.